Kenvue (NYSE:KVUE) Rating Increased to Buy at Rothschild & Co Redburn

Rothschild & Co Redburn upgraded shares of Kenvue (NYSE:KVUE) from a neutral rating to a buy rating in a research note released on Friday morning, MarketBeat Ratings reports. The firm currently has $22.00 price objective on the stock, down from their prior price objective of $22.50.

Other equities analysts have also recently issued reports about the company. Royal Bank Of Canada lowered their price target on Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a report on Friday, August 8th. JPMorgan Chase & Co. lowered their price target on Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a report on Friday, July 25th. UBS Group decreased their target price on Kenvue from $25.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, July 17th. Bank of America decreased their target price on Kenvue from $27.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, July 15th. Finally, Zacks Research raised Kenvue to a “strong sell” rating in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus target price of $23.12.

Kenvue Stock Performance

NYSE KVUE opened at $16.40 on Friday. The stock has a market cap of $31.48 billion, a PE ratio of 22.17, a P/E/G ratio of 2.36 and a beta of 0.83. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue has a twelve month low of $16.07 and a twelve month high of $25.17. The stock has a fifty day simple moving average of $20.37 and a 200-day simple moving average of $21.81.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. The business had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company’s revenue was down 4.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities analysts anticipate that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a yield of 5.1%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is 112.16%.

Institutional Investors Weigh In On Kenvue

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Kenvue by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock valued at $4,881,844,000 after purchasing an additional 4,101,880 shares in the last quarter. Geode Capital Management LLC raised its position in Kenvue by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock valued at $1,021,267,000 after purchasing an additional 604,953 shares in the last quarter. Independent Franchise Partners LLP raised its position in Kenvue by 233.4% in the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock valued at $654,388,000 after purchasing an additional 21,886,537 shares in the last quarter. American Century Companies Inc. raised its position in Kenvue by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock valued at $633,447,000 after purchasing an additional 8,436,166 shares in the last quarter. Finally, Norges Bank acquired a new stake in Kenvue in the 2nd quarter valued at about $537,418,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.